23:56 , Nov 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Colitis Mouse studies suggest exosome-like nanoparticles (ELNs) from the ginger plant or ginger-based nanovesicles loaded with ELN microRNA (miRNA) could help treat colitis. In a mouse model of colitis, ELNs derived from ginger or...
19:29 , Nov 7, 2018 |  BC Innovations  |  Translation in Brief

Expanding the reach of plant exosomes

A University of Louisville team has shown how plant-derived exosomes could mobilize the gut microbiome against colitis, broadening the range of potential indications for the technology beyond those the university already has in Phase I...
18:29 , May 15, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains Tannic acid conjugates of therapeutic proteins or viral particles could be used for cardiac-specific delivery of therapies for myocardial infarction (MI) and other heart diseases. The method involves conjugating therapeutic proteins or...
21:16 , May 17, 2017 |  BC Week In Review  |  Clinical News

Proteon's vonapanitase receives breakthrough therapy designation

Proteon Therapeutics Inc. (NASDAQ:PRTO) said FDA granted breakthrough therapy designation to vonapanitase to increase arteriovenous fistula (AVF) secondary patency in patients on or expected to start hemodialysis. The recombinant human elastase is in the Phase...
20:36 , May 12, 2017 |  BC Week In Review  |  Clinical News

Proteon ups Phase III PATENCY-2 enrollment

Proteon Therapeutics Inc. (NASDAQ:PRTO) will for the second time increase enrollment in the ongoing Phase III PATENCY-2 trial of vonapanitase to treat chronic kidney disease (CKD) to correct a calculation error in the trial’s statistical...
16:25 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

Vonapanitase: Ph III PATENCY-2 amended

Proteon amended the double-blind, placebo-controlled, North American Phase III PATENCY-2 trial of vonapanitase given immediately after radiocephalic AVF to increase enrollment to 500 patients from 300 and to establish secondary patency and fistula use for...
20:24 , Dec 16, 2016 |  BC Week In Review  |  Clinical News

Vonapanitase: Ph III PATENCY-1 data

Top-line data from the double-blind, U.S. Phase III PATENCY-1 trial in 313 CKD patients receiving or expecting hemodialysis who underwent surgical creation of a radiocephalic AVF showed that a single dose of 30 µg vonapanitase...
00:02 , Dec 14, 2016 |  BC Extra  |  Clinical News

Proteon crumbles after Phase III patency miss

Proteon Therapeutics Inc. (NASDAQ:PRTO) plummeted $7.40 (75%) to $2.50 after it said vonapanitase (formerly PRT-201 ) missed the primary endpoint in the Phase III PATENCY-1 trial in patients with chronic kidney disease (CKD). Compared to...
20:29 , Nov 11, 2016 |  BC Week In Review  |  Clinical News

Vonapanitase: Ph I started

Proteon began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate a single perivascular injection of vonapanitase delivered via micro-infusion catheter in up to 40 patients immediately following angioplasty of a distal popliteal, tibial...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Company News

PhaseBio, Duke University deal

PhaseBio granted the university exclusive rights to conjugate small molecule oncologic ( SMO ) drugs to PhaseBio’s Elastin-Like Polypeptide (ELP) technology. The resulting compounds are known as High Transition Temperature ELP-SMO ( HTT ELP-SMO). PhaseBio...